Harbin Jixianglong Biotech Co., Ltd. recalls Semaglutide
- Recalling company
- Harbin Jixianglong Biotech Co., Ltd.
- Product
- Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China
- Reason
- CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
- Classification
- Class II – may cause temporary or medically reversible health consequences
- Recall date
- Feb 13, 2026
- Reported
- Mar 11, 2026
- Distribution
- Nationwide within the United States
- Status
- Ongoing
- Quantity
- N/A
- Lot / codes
- Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027
- Company location
- Haerbin, N/A
- Recall type
- Voluntary: Firm initiated
- Recall number
- D-0379-2026
- Agency
- U.S. Food and Drug Administration (FDA)
View official FDA notice ↗ Search recall number D-0379-2026 in the FDA Enforcement Report. Also see FDA recall press releases.
If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.